Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)

被引：0
|
作者：
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
机构：
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E372 / E372
页数：1
相关论文
共 50 条
  • [21] Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
    Doebele, Robert
    Paz-Ares, Luis
    Farago, Anna F.
    Liu, Stephen V.
    Chawla, Sant P.
    Tosi, Diego
    Blakely, Collin M.
    Krauss, John C.
    Sigal, Darren
    Bazhenova, Lyudmila
    John, Tom
    Besse, Benjamin
    Wolf, Juergen
    Seto, Takashi
    Chow-Maneval, Edna
    Ye, Chenglin
    Simmons, Brian
    Demetri, George D.
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
    Demetri, G. D.
    Paz-Ares, L.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Kim, E. S.
    Blakely, C. M.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Multani, P. S.
    Johnson, A.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2018, 29 : 175 - 175
  • [23] Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
    Patel, M.
    Siena, S.
    Demetri, G.
    Doebele, R.
    Chae, Y.
    Conkling, P.
    Garrido-Laguna, I.
    Longo, F.
    Rolfo, C.
    Sigal, D.
    Drilon, A.
    Liu, S.
    Goto, K.
    Bazhenova, L.
    Lonardi, S.
    Ciardiello, F.
    Huang, X.
    Osborne, S.
    Aziez, A.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S232 - S233
  • [24] Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001
    Wolf, J.
    Liu, S. V.
    Paz-Ares, L.
    Hu, J.
    Cho, B. C.
    Krzakowski, M.
    Chung, C. H.
    Patel, M.
    Taylor, M.
    Zeuner, H.
    Aziez, A.
    Huang, X.
    Osborne, S.
    Farago, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 34 - 34
  • [25] Updated Efficacy and Safety of Entrectinib in Patients (PTS) with NTRK Fusion-Positive (NTRK plus ) Tumors: Integrated Analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
    Folprecht, Gunnar
    Rolfo, Christian
    Dziadziuszko, Rafal
    Doebele, Robert
    Demetri, George
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 216 - 217
  • [26] Entrectinib in NTRK fusion-positive breast cancer: integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Springfeld, C.
    Blakely, C.
    Le Tourneau, C.
    Lu, J.
    Waqar, S. N.
    Huang, X.
    Day, B-M
    Simmons, B.
    Barve, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 160 - 160
  • [27] Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Blakely, Collin
    Le Tourneau, Christophe
    Lu, Janice
    Waqar, Saiama N.
    Huang, Xinhui
    Day, Bannmo
    Simmons, Brian
    Barve, Minal
    CANCER RESEARCH, 2020, 80 (04)
  • [28] Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
    de Bono, Johann S.
    Concin, Nicole
    Hong, David S.
    Thistlethwaite, Fiona C.
    Machiels, Jean-Pascal
    Arkenau, Hendrik-Tobias
    Plummer, Ruth
    Jones, Robert Hugh
    Nielsen, Dorte
    Windfeld, Kristian
    Ghatta, Srinivas
    Slomovitz, Brian M.
    Spicer, James F.
    Yachnin, Jeffrey
    Ang, Joo Ern
    Mau-Srensen, Paul Morten
    Forster, Martin David
    Collins, Dearbhaile
    Dean, Emma
    Rangwala, Reshma A.
    Lassen, Ulrik
    LANCET ONCOLOGY, 2019, 20 (03): : 383 - 393
  • [29] Entrectinib in Locally Advanced / Metastatic ROS1 and NTRK Fusion-Positive (NTRK plus ) Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Springfeld, Christoph
    de Braude, Filippo
    Siena, Salvatore
    Barlesi, Fabrice
    Drilon, Alexander
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Doebele, Robert C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
  • [30] Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial
    Besse, Benjamin
    Baik, Christina
    Springfeld, Christoph
    Hervieu, Alice
    Moreno, Victor
    Bazhenova, Lyudmila
    Lin, Jessica J.
    Camidge, D. Ross
    Solomon, Benjamin
    Velcheti, Vamsidhar
    van der Wekken, Anthonie J.
    Felip, Enriqueta
    Uprety, Dipesh
    Trone, Denise
    Stopatschinskaja, Shanna
    Cho, Byoung Chul
    Drilon, Alexander
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12345